双功能的茶叶多醇-胺纳米颗粒用于综合性炎症抑制和粘膜修复炎症性肠道疾病中的粘膜
Li Tian1, Jiaxin Huang2, Youwei Xu3
1Department of Gastroenterology, The Third Xiangya Hospital of Central South University, Changsha, Hunan, 410013, China.
Biomaterials
|February 28, 2026
概括
新的茶叶多和血清素纳米粒子 (TPSNs) 提供了一种双重方法来治疗炎症性肠病 (IBD). 这些纳米颗粒有效降低炎症,促进肠道愈合,显示IBD治疗的希望.
科学领域:
- 胃肠道学和纳米医学
背景情况:
- 炎症性肠病 (IBD) 是一种慢性疾病,其特点是肠道炎症和屏障功能障碍.
- 目前的IBD治疗主要针对炎症,经常忽视关键的粘膜修复机制,导致不完全恢复和副作用.
研究的目的:
- 开发和评估用于IBD综合治疗的新型茶叶多和血清素纳米粒子 (TPSNs).
- 在一个单一的纳米疗法中结合表甲基酸盐 (EGCG) 和血清素 (5-HT) 的抗炎,抗氧化和粘膜修复特性.
主要方法:
- 通过EGCG和5-HT的氧化共聚合合成TPSN.
- 在斑马鱼和小鼠的硫酸 (DSS) 诱导的急性结肠炎和IL-10淘汰赛慢性结肠炎模型中评估了治疗疗效.
- 机理学研究研究了RONS清除,巨细胞再极化,热和NF-κB抑制以及MAPK/PI3K-AKT通路激活.
- TPSN被配制成一种热敏凝,用于直肠输送.
主要成果:
- 在体内,TPSN显著减少了结肠炎的严重程度,并改善了其组织病理特征.
- 机理学研究证实了TPSN捕获RONS的能力,促进M2巨分化,抑制热和NF-κB,并激活MAPK/PI3K-AKT通路.
- 带有TPSN的凝通过直肠输送,增强局部和持续的药物释放.
- 生物安全评估显示,没有显著的器官毒性或肝/功能受损.
结论:
- TPSN代表了IBD的一个有前途的纳米治疗策略,有效地解决炎症和粘膜修复.
- 开发的直肠输送系统确保局部和持续的治疗效果.
- TPSN为IBD综合管理提供了安全有效的选择.
更多相关视频
相关概念视频
01:29Drugs for Treatment of Ulcerative Colitis in IBD
577
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
577
01:29Inflammatory Bowel Disease IV: Pharmacological Management
862
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
862
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
660
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
660
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
1.3K
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
1.3K
01:21Drugs for Treatment of Constipation-Predominant IBS
1.0K
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
1.0K
01:17Drugs for Treatment of Diarrhea-Predominant IBS
799
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
799